ACXP — Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals (ACXP) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash Position: Ended Q3 2025 with $5.9 million in cash, up from $3.7 million at year-end 2024.
• Funding: Raised approximately $1.7 million through an equity line of credit and an additional $1.4 million from warrant exercises post-quarter.
• R&D Expenses: $0.4 million for Q3 2025, down from $1.2 million in Q3 2024. Year-to-date R&D expenses totaled $1.6 million, compared to $4.6 million in the prior year.
• G&A Expenses: Steady at $1.6 million for Q3 2025, consistent with Q3 2024. Year-to-date G&A expenses were $4.9 million, down from $6.8 million in the previous year.
• Net Loss: Reported a net loss of $2 million ($1.23 per diluted share) for Q3 2025, an improvement from a $2.8 million loss ($3.45 per diluted share) in Q3 2024.

2. Strategic Updates and Business Highlights:

• Stock Split: Implemented a 1-for-20 reverse stock split to regain NASDAQ compliance, which was successful.
• Patent Developments: Received a new patent in Australia for DNA polymerase 3C inhibitors, adding to existing U.S. and international patents.
• Clinical Updates: Presented at ID Week regarding ibezapolstat's microbiome-sparing properties, showing potential advantages over existing antibiotics.
• Publications: A significant publication in Nature Communications detailing the binding of ibezapolstat to its target, enhancing the scientific foundation for the drug's development.

3. Forward Guidance and Outlook:

• Clinical Trials: Actively seeking funding for a Phase 3 trial for ibezapolstat, with plans for a secondary trial targeting patients with recurrent C. diff infections.
• Economic Impact: If approved, ibezapolstat could significantly reduce the annual U.S. cost burden associated with C. diff infections, which is estimated at $5 billion.

4. Challenges and Points of Concern:

• Regulatory Environment: Uncertainty regarding the impact of recent FDA leadership changes and the status of the PASTOR Act on antibiotic funding.
• Partnership Discussions: While optimistic about potential partnerships, the timeline remains uncertain, and the company is cautious about expectations.
• Operational Costs: Although operational expenses are currently stable, the company is focused on further cost-cutting measures to extend its financial runway.

5. Notable Q&A Insights:

• Regulatory Strategy: The company is monitoring new FDA initiatives but remains committed to its existing strategy, including pursuing Phase 3 trials.
• Partnership Potential: Management expressed optimism about potential partnership announcements in the near future, indicating ongoing discussions.
• Cost Management: The company is focused on maintaining a lean operation, with expectations of gradually decreasing operational costs.

Overall, Acurx Pharmaceuticals demonstrated improved financial metrics and strategic advancements in Q3 2025, while navigating regulatory uncertainties and focusing on cost management as it prepares for future clinical trials.